

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



30th May, 2025

To,
The Manager,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 539206

Company Symbol: GVBL

Sub: Outcome of the Board meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on today i.e. 30th May 2025

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held on Friday, 30th May 2025, at the Registered office of the Company situated at G-74, Pushkar Enclave Paschim Vihar, Delhi - 110063 to consider and approve the following matter(s): -

1. Considered and approved the standalone audited financial results of the company for the quarter and financial year ended 31st March 2025. A copy of the said standalone audited financial results along with the Auditor Report of the Statutory Auditor thereon is enclosed herewith;
2. Appointment of Mr. Yogainder Kumar Gupta (DIN: 03094998) as an 'Additional Director' in the category of Non-Executive – Independent Director on the Board of Directors of the Company w.e.f., Friday, 30th May, 2025 to hold office for a term of 5 (five) consecutive years upto May 29, 2030, subject to the approval of the shareholders in the General Meeting pursuant to section 149, 150, 152 read with Schedule IV and Section 161(1) read with Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions, sections, rules of the companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force).

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, attached below as **Annexure A**.

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



3. Appointment of M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057) as the Secretarial Auditors of the Company for Financial year 24-25.
The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, attached below as **Annexure B**.
4. Considered Reconstitution of the Committees - Audit Committee, Stakeholders' Relationship Committee (SRC), Nomination and Remuneration Committee (NRC), Risk Management Committee as per the provisions of the Companies Act, 2013 and the SEBI (LODR) Regulations, 2015.

The meeting of the Board of Directors commenced at 02:30 P.M. and concluded at 04:00 P.M.

This is for your information and record please.

Thanking you,
Yours sincerely,

For Genomic Valley Biotech Limited

Yogesh
Agrawal

Digitally signed
by Yogesh
Agrawal
Date: 2025.05.30
16:15:27 +05'30'

Yogesh Agrawal
Managing Director
DIN : 01165288

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Annexure-A

Particulars of appointment of Mr. Yogainder Kumar Gupta as Non-Executive – Independent Director of the Company

Sr. No.	Particulars	Details
a)	Name of Person	Mr. Yogainder Kumar Gupta
b)	Reason for change viz. appointment, resignation, removal, death or otherwise	Upon the recommendation of the Nomination & Remuneration Committee Mr. Yogainder Kumar Gupta, appointed as Additional Director (Non-Executive, Independent) subject to approval of the shareholders in their meeting.
c)	Date of appointment / Cessation (as applicable)	30-05-2025
d)	Terms of appointment	For 5 (five) consecutive years from May 30, 2025 to May 29, 2030.
e)	Brief profile (in case of appointment)	<p>Yogainder Kumar Gupta is having Experience in the field of Finance and real estate of 44 years. He has completed his graduate with Degree of Bachelors of Commerce (B.Com).</p> <p>He started his career at a tender age and has gained exposure to many fields in the past few years enhancing his core skills and expertise. He carries an intellectual personality and has relevant expertise.</p>
f)	Disclosure of relationships between directors (in case of appointment of a director)	No Relationship with existing director of the Company.

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Annexure- B

Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars	Details
a)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
b)	Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/re-appointment	Appointment is for Financial Year 24-25
c)	Brief profile (in case of appointment)	M/s SBR & Co. LLP, is a firm of Company Secretaries, established in the year 2019, based at Navi Mumbai and having branch office at Ghaziabad, with an experience of more than 6 years. M/s SBR & Co. LLP, Company Secretaries has been quality reviewed by the Institute of Company Secretaries of India (ICSI), peer reviewed by the ICSI.
d)	Disclosure of relationships between directors (in case of appointment of a director)	Not applicable

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

Independent Auditor's Report on the Financial Result of
Genomic Valley Biotech Limited.

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

Subject: Auditor's Report on the Audited Financial Results for the Quarter and year ended
March 31, 2025

Opinion

We have audited the accompanying statement of financial results of Genomic Valley Biotech Limited ("the Company") for the quarter and year ended 31st March, 2025 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


- i. is presented in accordance with the requirements of regulation 33 the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the recognition and measurement Principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit/(loss) and other comprehensive income and other financial information of the Company for the quarter and year then ended 31st March, 2025.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the companies Act, 2013, ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results for the quarter and year ended 31st March, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The management of the Company is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/(loss) and other comprehensive income of the Company and other financial information in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for



safeguarding of the Assets of the Company and for preventing and detecting frauds and other Irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting Process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference financial statements in place and the operating effectiveness of such controls,
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management of the company.
- Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulation
- Conclude on the appropriateness of the board of director's use of going concern basis of accounting and, based on audit evidence obtained, whether the material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's reports to the related disclosures in the financial result or, If such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future event or condition may cause the Company, to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Result.




We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit,

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended 31st March, 2025 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of the above matter.



For ANDROS & CO.
Chartered Accountants

A large, stylized handwritten signature in blue ink, written over the circular stamp and extending to the right.

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

UDIN: 25502310BMGUFL1272


Place: Delhi
Date: 30-05-2025

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2025

In Rs.

Sr. No.	Particular	For the quarter ended			For the year ended	
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue From Operations	26,35,094	22,00,950	-	84,39,394	16,50,750
II	Other Income	676	4,308	-	44,660	15,003
III	Total Revenue (I+II)	26,35,770	22,05,258	-	84,84,054	16,65,753
IV	Expenses					
	Cost of materials consumed	-	-	-	-	-
	Purchases of Stock-in-Trade	48,56,220	-	-	48,56,220	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-28,42,425	-	-	-28,42,425	-
	Employee benefits expense	4,14,000	3,20,645	45,000	12,08,645	3,75,000
	Financial costs	-	-	-	-	-
	Depreciation and amortization expense	10,414	5,000	2,732	25,414	10,925
	Other expenses	1,79,012	3,25,857	3,98,600	8,21,824	11,28,348
	Total Expenses (IV)	26,17,222	6,51,502	4,46,332	40,69,678	15,14,273
V	Profit / (Loss) before exceptional item and tax (III-IV)	18,548	15,53,756	-4,46,332	44,14,376	1,51,480
VI	Exceptional Item	-	-	-	-	-
VII	Profit/loss before Tax (V-VI)	18,548	15,53,756	-4,46,332	44,14,376	1,51,480
VIII	Tax expenses					
	(1) Current Tax	8,50,000	-	-	8,50,000	-
	(2) Deferred Tax	3,444	-	-339	3,444	-339
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	-8,34,895	15,53,756	-4,45,993	35,60,932	1,51,818
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	-8,34,895	15,53,756	-4,45,993	35,60,932	1,51,818
XIV	Other Comprehensive Income	-	-	-	-	-
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-



	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	-8,34,895	15,53,756	-4,45,993	35,60,932	1,51,818
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	30,54,500	30,54,500	30,54,500	30,54,500	30,54,500
XVII	Earning Per Equity Share (for continuing operation):					
	1) Basic	-0.2733	0.51	-0.15	1.17	0.05
	2) Diluted	-0.2733	0.51	-0.15	1.17	0.05
XVIII	Earning Per Equity Share (for discontinued operation):					
	1) Basic	0.0000	0.00	0.00	0.00	0.00
	2) Diluted	0.0000	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):					
	1) Basic	-0.2733	0.51	-0.15	1.17	0.05
	2) Diluted	-0.2733	0.51	-0.15	1.17	0.05

Place : New Delhi
Date : 30.05.2025
UDIN: 25502310BMGUFL1272



For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited

Yogesh Agrawal
Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L011221HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2025

Statement of Asset and Liabilities

Particulars	As at	
	31-03-2025	31-03-2024
	Audited	Audited
	Standalone	Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	87,004	20,656
Capital work in progress	-	-
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets	-	-
Investment	-	1,66,660
Loans	1,72,11,439	1,40,00,000
Security Deposits	50,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	-	-
Other non current assets	-	-
Total Non-Current Assets	1,73,48,443	1,42,37,316
Current Assets		
Inventories	28,42,425	-
Financial Assets:	-	-
Investments	-	-
Trade Receivables	2,21,44,945	2,53,01,145
Cash and Cash equivalents	2,28,976	22,844
Other Balances with banks	2,23,261	37,890
Loans	-	-
Other financial assets	-	-
Other Current assets	7,77,574	37,37,529
Total Current Assets	2,62,17,181	2,90,99,408
Total Assets	4,35,65,624	4,33,36,724
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	3,05,45,000	3,05,45,000
Othe Equity	84,36,533	48,75,601
Total Equity	3,89,81,533	3,54,20,601
Non Current Liabilities		



Financial liabilities		
Borrowings	-	-
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	5,283	1,840
Provisions	-	-
Other Non Current liabilities	-	-
Total Non Current Liabilities	5,283	1,840
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	97,280	60,19,146
Other Financials liabilities	26,54,338	-
Provisions	8,75,000	25,000
Other Current liabilities	9,52,190	18,70,137
Total Current Liabilities	45,78,808	79,14,283
TOTAL EQUITY AND LIABILITIES	4,35,65,624	4,33,36,724

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 30.05.2025 and the Statutory Auditors of the company have audited these financials results.

The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.



Place : New Delhi
Date : 30.05.2025
UDIN: 25502310BMGUFL1272

For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited

(Signature)
Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 March, 2025

Particulars	Amount in INR	
	31.03.2025	31.03.2024
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit As Statement Profit & Loss	44,14,376	1,51,480
Adjustment For		
Discount received	-	-
Non-Operating Income	-44,660	-15,003
Interest Income	-	-
Loss on sale of assets	-	-
Depreciation and Amortisation Expenses	25,414	10,925
Operating Profit Before Change in Working Capital	43,95,130	1,47,402
ADJUSTMENTS FOR WORKING CAPITAL:		
Increase/Decrease in Loans and Advances	-32,11,439	43,50,593
Decrease/ (Increase) in Inventories	-28,42,425	-
Increase/Decrease in Security Deposits	-	-
Increase/Decrease in Trade Receivables	31,56,200	-31,26,320
Increase/Decrease in Other Current Assets	29,59,955	-5,53,708
Increase/Decrease in Current Liabilities	-33,32,032	-10,18,669
CASH GENERATED FROM OPERATIONS	11,25,389	-2,00,702
Taxes Paid	8,53,444	-
Total (A)	2,71,945	-2,00,702
B. CASH FLOW FROM INVESTING ACTIVITIES		
Additions/Sales to fixed assets	-91,763	-
Purchase/Sell of Investments	1,66,660	-1,66,660
Discount received	-	-
Non-Operating Income	44,660	15,003
Interest Income	-	-
Total (B)	1,19,557	-1,51,657
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	-	-
Preliminary Expenses	-	-
Total (C)	-	-
NET CASH FLOWS DURING THE YEAR (A+B+C)	3,91,503	-3,52,358
Cash and Cash Equivalents (Opening Balance)	60,734	4,13,092
Cash and Cash Equivalents (Closing Balance)	4,52,237	60,734



Place : New Delhi
Date : 30.05.2025
UDIN: 25502310BMGUFL1272

For and on behalf of the Board of Directors of
Genomic Valley Biotech Limited

(Signature)
Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



30th May, 2025

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 539206

Sub: Declaration on Audit Reports with an unmodified opinion

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s ANDROS & Co. Chartered Accountants (firm Registration no. 008976N), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the quarter and financial year ended March 31, 2025.

Kindly take the same on record.

Thanking you,

For Genomic Valley Biotech Limited

Yogesh
Agrawal
al

Digitally signed
by Yogesh
Agrawal
Date:
2025.05.30
16:16:33 +05'30'

Yogesh Agrawal
Chairman & Managing Director
DIN : 01165288
Add:- G-74, Pushkar Enclave,
Paschim Vihar, Delhi – 110063

Investor E-mail id: genomicvalley@gmail.com